Gain insight into the optimal management of patients with progressive metastatic pancreatic adenocarcinoma and learn how to select first-line and second-line treatment based on evidence and current guidelines. Furthermore, explore the high prevalence of malnutrition in patients with this disease learn about the importance of early nutrition intervention. This activity features expert faculty video presentations with downloadable slides from our satellite symposium held in conjunction with the ESMO 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Aug 1, 2017
Aug 1, 2018
Setting the stage: Accomplishments and challenges in the management of metastatic pancreatic adenocarcinoma
Michel Ducreux, MD, PhD
Case 1—Metastatic pancreatic adenocarcinoma: What therapy should I select first?
Marc Peeters, MD, PhD
Case 2—Optimal management of progressive metastatic pancreatic adenocarcinoma: Second-line therapy and beyond
Gerald Prager, MD
Importance of nutrition in pancreatic cancer care
Federico Bozzetti, MD
Future perspectives and prIME Points™
Michel Ducreux, MD, PhD
Michel Ducreux, MD, PhDGustave Roussy
Federico Bozzetti, MDSurgical oncologist
Marc Peeters, MD, PhDAntwerp University Hospital
Gerald Prager, MDMedical University of Vienna
This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers outside of the United States involved in the management of patients with pancreatic cancer.
After successful completion of this educational activity, participants should be able to:
- Select the most appropriate treatment approach for newly diagnosed metastatic pancreatic adenocarcinoma based on patient and disease characteristics
- Identify optimal treatment strategies for patients with progressive pancreatic cancer (second-line therapy and beyond)
- Assess supportive care measures including importance of nutrition throughout the course of pancreatic cancer management
This educational activity is supported by grants from Nutricia and Shire.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.